Cargando…

Immune Checkpoints OX40 and OX40L in Small-Cell Lung Cancer: Predict Prognosis and Modulate Immune Microenvironment

BACKGROUND: OX40 and OX40 ligand (OX40L), as essential immune checkpoint (IC) modulators, are highly correlated with cancer immunity regulation as well as tumor microenvironment (TME). Immunotherapy showed outstanding advantages in small-cell lung cancer (SCLC) therapy. However, functions and clinic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Peixin, Wang, Hao, Zhao, Lishu, Guo, Haoyue, Zhang, Liping, Zhang, Wei, Sun, Chenglong, Zhao, Sha, Li, Wei, Zhu, Jun, Yu, Jia, Wu, Chunyan, He, Yayi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8652148/ https://www.ncbi.nlm.nih.gov/pubmed/34900670 http://dx.doi.org/10.3389/fonc.2021.713853

Ejemplares similares

OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
por: Deng, Juan, et al.
Publicado: (2019)

Controversial Role of the Immune Checkpoint OX40L Expression on Platelets in Breast Cancer Progression
por: Rittig, Susanne M., et al.
Publicado: (2022)

Increased Expressions of OX40 and OX40 Ligand in Patients with Primary Immune Thrombocytopenia
por: Cui, Dawei, et al.
Publicado: (2019)

Analysis of the OX40/OX40L immunoregulatory axis combined with alternative immune checkpoint molecules in pancreatic ductal adenocarcinoma
por: Chen, Xianlong, et al.
Publicado: (2022)

OX40L–OX40 Signaling in Atopic Dermatitis
por: Furue, Masutaka, et al.
Publicado: (2021)

OX40/OX40 Ligand Interactions in T-Cell Regulation and Asthma
por: Kaur, Davinder, et al.
Publicado: (2012)

OX40/OX40L axis: not a friend in autoimmunity
por: Ueno, Hideki, et al.
Publicado: (2015)

Roles of OX40 and OX40 Ligand in Mycosis Fungoides and Sézary Syndrome
por: Kawana, Yuki, et al.
Publicado: (2021)

New pathways in immune stimulation: targeting OX40
por: Alves Costa Silva, Carolina, et al.
Publicado: (2020)

Crucial role of OX40/OX40L signaling in a murine model of asthma
por: Lei, Wei, et al.
Publicado: (2018)

Immunostimulation by OX40 Ligand Transgenic Ewing Sarcoma Cells
por: Reuter, Dajana, et al.
Publicado: (2015)

OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
por: Linch, Stefanie N., et al.
Publicado: (2015)

The T cell-B cell interaction via OX40-OX40L is necessary for the T cell-dependent humoral immune response
Publicado: (1996)

Airway Wall Expression of OX40/OX40L and Interleukin-4 in Asthma
por: Siddiqui, Salman, et al.
Publicado: (2010)

Expression of gp34 (OX40 Ligand) and OX40 on Human T Cell Clones
por: Takasawa, Naruhiko, et al.
Publicado: (2001)

Clinical Significance of OX40 and OX40 Ligand in the Peripheral Blood of Patients with Myasthenia Gravis
por: Zhou, Xiaoling, et al.
Publicado: (2022)

OX40L-OX40 Interactions: A Possible Target for Gastrointestinal Autoimmune Diseases
por: Mahmood, Tahrin, et al.
Publicado: (2012)

OX40-OX40L Inhibition for the Treatment of Atopic Dermatitis—Focus on Rocatinlimab and Amlitelimab
por: Lé, Ana Maria, et al.
Publicado: (2022)

Therapeutic strategies for the costimulatory molecule OX40 in T-cell-mediated immunity
por: Fu, Yu, et al.
Publicado: (2020)

Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia
por: Marconato, Maddalena, et al.
Publicado: (2022)

OX40: a win–win path to tumor immunity
por: Sedwick, Caitlin
Publicado: (2008)

OX40/OX40L in systemic lupus erythematosus: Association with disease activity and lupus nephritis
por: Farres, Mohamed N., et al.
Publicado: (2011)

An OX40L mRNA vaccine inhibits the growth of hepatocellular carcinoma
por: Deng, Zhuoya, et al.
Publicado: (2022)

Expression of the Immune Checkpoint Modulator OX40 in Acute Lymphoblastic Leukemia Is Associated with BCR-ABL Positivity()
por: Rothfelder, Kathrin, et al.
Publicado: (2018)

The OX40/OX40L Axis Regulates T Follicular Helper Cell Differentiation: Implications for Autoimmune Diseases
por: Fu, NanNan, et al.
Publicado: (2021)

Serum Levels of OX40 in Early and Late-Stage Oral Squamous Cell Carcinoma
por: Sani, Aliya I, et al.
Publicado: (2021)

OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy
por: Shibahara, Ichiyo, et al.
Publicado: (2015)

Hsa_circ_0000652 Aggravates Inflammation by Activation of Macrophages and Enhancement of OX40/OX40L Interaction in Ankylosing Spondylitis
por: Song, Minkai, et al.
Publicado: (2021)

Locally secreted Fc-OX40L is superior to systemic, antibody mediated, OX40 costimulation for combination immunotherapy
por: Fromm, George, et al.
Publicado: (2015)

OX40L/OX40 Signal Promotes IL-9 Production by Mucosal MAIT Cells During Helicobacter pylori Infection
por: Ming, Siqi, et al.
Publicado: (2021)

OX40 and 4-1BB delineate distinct immune profiles in sarcoma
por: Melake, MJ, et al.
Publicado: (2022)

Mast Cell-Derived Exosomes Promote Th2 Cell Differentiation via OX40L-OX40 Ligation
por: Li, Fei, et al.
Publicado: (2016)

Synovial Macrophages Expression of OX40L Is Required for Follicular Helper T Cells Differentiation in the Joint Microenvironment
por: Cai, Xiaoyu, et al.
Publicado: (2022)

Enhancement of the Soluble Form of OX40 and OX40L Costimulatory Molecules but Reduction of the Membrane Form in Type 1 Diabetes (T1D)
por: An, Jingnan, et al.
Publicado: (2019)

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy
por: Fromm, George, et al.
Publicado: (2018)

Prevalence analysis of OX40-positive cell populations in solid tumors
por: Ziai, James, et al.
Publicado: (2015)

OX40-OX40L Interaction Promotes Proliferation and Activation of Lymphocytes via NFATc1 in ApoE-Deficient Mice
por: Yan, Jinchuan, et al.
Publicado: (2013)

Development of OX40 agonists for canine cancer immunotherapy
por: Ruiz, Damien, et al.
Publicado: (2022)

The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis
por: Ma, Jiajia, et al.
Publicado: (2022)

Human leukocyte antigen class II-based immune risk model for recurrence evaluation in stage I–III small cell lung cancer
por: Chen, Peixin, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h8i8rt1p8jutfnohn47p5g4dgb